Royal Bank Of Canada Graphite Bio, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.24 - $2.66 $2,184 - $2,593	975 Added 14.56%	7,673 $20,000
Q3 2023 Nov 14, 2023	SELL	$2.18 - $2.77 $3,095 - $3,933	-1,420 Reduced 17.49%	6,698 $16,000
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $20,034 - $27,415	8,111 Added 115871.43%	8,118 $21,000
Q4 2022 Feb 14, 2023	BUY	$2.82 - $3.59 $19 - $25	7 New	7 $0
Q2 2022 Aug 15, 2022	SELL	$2.14 - $5.23 $3,879 - $9,481	-1,813 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.1 - $13.06 $6,905 - $17,683	-1,354 Reduced 42.75%	1,813 $9,000
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $10,520 - $20,904	1,251 Added 65.29%	3,167 $39,000
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $29,786 - $53,486	1,884 Added 5887.5%	1,916 $32,000
Q2 2021 Aug 16, 2021	BUY	$18.5 - $30.73 $592 - $983	32 New	32 $1,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.